Rare side effect of adjuvant ipilimumab after surgical resection of melanoma: Guillain-Barré syndrome

Patel, Rohini J.; Liu, Michael A.; Amaraneni, Akshay; Sindhu, Simran

doi:10.1136/bcr-2017-221318

Cited by 6 publications

(4 citation statements)

References 24 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…54.5% (18/33) of cases were consistent with AIDP [ 16 – 19 , 21 , 22 , 24 , 26 – 30 , 33 , 34 , 39 , 42 ] and axonal damage accounted for 12.1% (4/33, AMSAN: 3 and AMAN: 1) [ 15 , 23 , 25 , 27 ]. The subtypes in four cases were equivocal because they showed mixed features of axonal injury and demyelination [ 23 , 31 , 35 , 36 ]. There were also three cases, two with MFS [ 13 , 20 ] and the other with MFS-GBS overlap [ 32 ].…”

Section: Resultsmentioning

confidence: 99%

“…Slight pleocytosis (i.e., cell count > 5/ μ l) was detected in 4/33 cases (12.1%) with a maximum cell count of 15/ μ l and a median CSF protein of 115 mg/dl [ 15 , 19 , 27 , 37 ]. CSF protein values and cell counts were normal in three cases [ 23 , 25 , 35 ], and there was elevated CSF immunoglobulin G levels in one case [ 25 ].…”

Section: Resultsmentioning

confidence: 99%

See 1 more Smart Citation

Guillain-Barré Syndrome-Like Polyneuropathy Associated with Immune Checkpoint Inhibitors: A Systematic Review of 33 Cases

Zhang

Zhao

2021

BioMed Research International

View full text Add to dashboard Cite

Immune checkpoint inhibitors (ICIs) have been increasingly used in the treatment of various types of tumors with favorable results. But these treatments also led to a variety of immune-related adverse events (irAEs). Neurological irAEs such as Guillain-Barré Syndrome are rare and may have serious consequences once they occur. A systematic literature search was performed in PubMed and Embase for all case reports of GBS associated with ICIs published in English reporting on human beings from 1990 up to date. A total of 30 case reports ( total patients = 33 ) were used for final analysis. The included cases were from 11 countries, covering 10 tumor types, with melanoma accounting for the largest number. The mean age was 62.2 ± 11.1 years old, and males were dominant (male: 26 and female: 7). The median time of initial symptoms was 8.2 weeks after the 1st dose of ICIs. The most common manifestations of GBS associated with ICIs were weakness, hyporeflexia or areflexia, and paresthesia in order. The GBS subtypes suggested by electrophysiological results were acute inflammatory demyelinating polyneuropathy (AIDP), acute motor axonal neuropathy (AMAN), and Miller Fisher syndrome (MFS). The protein level of CSF in patients with GBS related to ICIs was 180.68 ± 152.51 mg/dl. Immediate termination of ICIs followed by intravenous immunoglobulin was the preferred treatment option. 72.7% of patients recovered or had residual mild dysfunction after treatment. Elderly male patients with melanoma were most likely to develop ICI-related GBS. The specific neurological symptoms, CSF analysis, and electrophysiological examination were important means of diagnosis.

show abstract

Section: Resultsmentioning

confidence: 99%

Section: Resultsmentioning

confidence: 99%

Guillain-Barré Syndrome-Like Polyneuropathy Associated with Immune Checkpoint Inhibitors: A Systematic Review of 33 Cases

Zhang

Zhao

2021

BioMed Research International

View full text Add to dashboard Cite

show abstract

“…4 5 The link between checkpoint inhibitors and the development of GBS has been described in case reports. [6][7][8][9][10][11] Conversely, there have been reports highlighting the safety of ICI administration in patients with a history of GBS. [12][13][14] This data alerts us to the importance of understanding the incidence of this type of event with the ICI class.…”

Section: Open Accessmentioning

confidence: 99%

“…Guillain-Barré syndrome (GBS) is a rare neurological disorder characterised by the immune system’s misguided attack on the peripheral nerves, resulting in muscle weakness and paralysis and is the most common cause of flaccid paralysis worldwide 4 5. The link between checkpoint inhibitors and the development of GBS has been described in case reports 6–11. Conversely, there have been reports highlighting the safety of ICI administration in patients with a history of GBS 12–14…”

Section: Introductionmentioning

confidence: 99%

Guillain-Barré syndrome and checkpoint inhibitor therapy: insights from pharmacovigilance data

Abrahao,

Tenório,

Rodrigues

et al. 2024

BMJ Neurol Open

View full text Add to dashboard Cite

BackgroundThere are increasing reports of cases of Guillain-Barré syndrome (GBS), as an adverse event of an immune checkpoint inhibitor (ICI) but postmarket data on the incidence of this remains scarce. This study sought to conduct a comprehensive review of GBS events arising as a secondary outcome of ICI treatments in real-world patients, using the Food and Drug Administration Adverse Event Reporting System (FAERS).MethodsData covering the period from the third quarter of 2003 to the second quarter of 2023 were extracted from the FAERS database. GBS cases (associated with the usage of avelumab, atezolizumab, ipilimumab, nivolumab and pembrolizumab) were subjected to disproportionality analysis to detect potential signals.ResultsA total of 2208 reports of GBS were identified within the FAERS database, with 242 of these cases (10.9%) being associated with ICIs. All five drugs exhibited a disproportionality in the reporting of adverse events, with the highest observed for avelumab (reporting OR, ROR: 29.8), followed by atezolizumab (ROR: 17.0), ipilimumab (ROR: 16.0), pembrolizumab (ROR: 11.9) and nivolumab (ROR: 8.2).ConclusionThese checkpoint inhibitors are associated with a statistically significant disproportionate number of reports of GBS as an adverse event, with avelumab being the ICI with the highest association. The present pharmacovigilance study serves as a valuable tool, offering a more comprehensive and nuanced perspective on GBS associated with ICIs. This study contributes to a deeper comprehension of this rare adverse drug effect.

show abstract

Ipilimumab

2018

Reactions Weekly

View full text Add to dashboard Cite

Rare side effect of adjuvant ipilimumab after surgical resection of melanoma: Guillain-Barré syndrome

Cited by 6 publications

References 24 publications

Guillain-Barré Syndrome-Like Polyneuropathy Associated with Immune Checkpoint Inhibitors: A Systematic Review of 33 Cases

Guillain-Barré Syndrome-Like Polyneuropathy Associated with Immune Checkpoint Inhibitors: A Systematic Review of 33 Cases

Guillain-Barré syndrome and checkpoint inhibitor therapy: insights from pharmacovigilance data

Ipilimumab

Contact Info

Product

Resources

About